CAMP4 Therapeutics Corporation
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CAMP research report →
Range $6.5 – $15
Price Chart
About the company
CAMP4 Therapeutics Corporation, a biotechnology firm, was established in 2015 by Richard A. Young and Leonard Zon. Based in Cambridge, Massachusetts, its core focus is the identification and development of new therapeutic solutions for patients.
- CEO
- Joshua Mandel-Brehm
- IPO
- 2024
- Employees
- 48
- HQ
- Cambridge, MA, US
Get TickerSpark's AI analysis on CAMP
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $94.73M
- P/E
- -2.00
- PEG
- -0.13
- P/S
- 22.47
- P/B
- -372.82
- EV/EBITDA
- -0.15
- Div Yield
- 0.00%
- Gross Margin
- 77.80%
- Op Margin
- -1242.50%
- Net Margin
- -2543.74%
- ROE
- -314.08%
- ROIC
- -69.76%
Latest fiscal year · YoY change
- Revenue
- $3.50M+436.5%
- Gross Profit
- $1.86M+185.1%
- Op Income
- $-52,061,000
- Net Income
- $-80,403,000-55.2%
- EPS
- $-2.65+0.4%
- OCF Growth
- +35.1%
- FCF Growth
- +35.2%
- 52W High
- $7.75
- 52W Low
- $1.41
- 50D MA
- $4.10
- 200D MA
- $4.48
- Beta
- 0.21
- RSI (14)
- 53
- Avg Volume
- 229.62K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
CalAmp reported a soft fiscal Q1 as supply-chain disruptions hit hardware revenue, but subscription growth, RPO expansion, and customer conversions continued to progress.· January 14, 2026
- Total revenue was $64.7 million, down 19% year over year, as China lockdowns and supply constraints limited shipments.
- Software and subscription services revenue rose 13% year over year to $39.6 million and reached about 61% of total revenue.
- The company said it converted about one-third of its eligible telematics device customers to multi-year subscription contracts, with the rest targeted by fiscal year-end.
- Adjusted EBITDA was $1.9 million, or 3% margin, versus $8.4 million and 11% a year ago; gross margin was 40%.
- Management expects second-quarter revenue to grow sequentially in the mid to high single-digit range, but it is still not giving quarterly guidance.
CalAmp reported fiscal Q1 revenue of $64.7 million, down 5% sequentially from $68.4 million and down 19% year over year from $79.7 million. Software and subscription services revenue was $39.6 million, up 13% year over year and down 4% sequentially, while telematics products revenue was $25.2 million, down 7% sequentially and 44% year over year. Consolidated gross margin was 40% versus 41% in both the prior quarter and the same quarter last year. Adjusted EBITDA was $1.9 million with a 3% margin, compared with $5 million and 7% last quarter and $8.4 million and 11% a year ago. Cash and cash equivalents were about $59 million, down from $79 million last quarter, and aggregate outstanding debt was approximately $233 million, including $230 million of 2% convertible senior notes due August 2025. For Q2 fiscal 2023, management maintained its policy of not providing quarterly guidance but said it expects sequential revenue growth in the mid to high single-digit percentage range.
Jeff Gardner framed the quarter as continued progress in transforming CalAmp into a recurring SaaS telematics business. He emphasized that new sales will now involve subscriptions, noted the one-third conversion milestone, and pointed to customer wins including BMW, Volkswagen Leasing, Brigham Young University, Grupo Salinas, Bristlecone, and assured Techmatics. His tone was optimistic but candid about near-term disruption from supply chain issues and the pace of the transformation.
Kurt Binder focused on the financial impact of supply shortages and the mix shift underway. He cited $64.7 million of revenue, 40% gross margin, $1.9 million of adjusted EBITDA, and $59 million of cash, and explained that cash declined because of lower operating cash flow and higher deferred billings tied to multi-year subscription conversions. He also said the company is renewing its revolving line of credit, expects to finalize it in the coming weeks, and reiterated that medium- to long-term gross margin remains targeted toward 50% as mix shifts to software and subscription revenue.
Analysts pressed on why software and subscription revenue was down sequentially despite strong conversion activity, and management said the decline reflected GAAP revenue timing, runoff in the legacy vehicle finance business, and some contracts tapering before renewal. Questions also focused on gross margin progression, with management saying near-term margins remain under pressure from components, freight, and tariffs, but should improve as supply chain conditions ease and revenue mix shifts further to software. On ARPU and BMW, management said the BMW program is a meaningful pan-European land-and-expand opportunity and that near-term ARPU may face some pressure from lower-ARPU conversion customers before improving over time with new logos and upsells.
The core positive is that recurring revenue is growing, now more than 60% of total revenue, and the eligible customer conversion process is ahead of schedule with about one-third completed. Management also highlighted rising RPO to about $215 million and subscriber count up 25% year over year to 1.2 million, which supports future visibility.
The main risks are still supply chain related: revenue fell 19% year over year, hardware shipments were constrained by China lockdowns, and management said visibility into product shipments remains uncertain. Gross margin slipped to 40%, cash fell to $59 million, debt remains substantial at about $233 million, and the company acknowledged that the revenue and ARPU transition could create near-term pressure before the subscription model fully scales.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 13.1%
- Shares Outstanding
- 21.24M
- Float Shares
- 2.78M
of shares held by institutions
39 13F filers
Buy/sell ratio 6.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Janus Henderson Group PLC | 6.31M | 0 |
| Vanguard Group Inc | 1.67M | ▲ 1.36M |
Held by 67 ETFs
Biggest fund positions in CAMP by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 19, 26 | Tardiff Daniel | sell | 1,738 |
| Aug 3, 26 | 5AM Partners VI, LLC | buy | 3,179,558 |
| Aug 3, 26 | Schwab Andrew J. | other | 3,179,558 |
| Aug 3, 26 | Young Richard A | buy | 16,378 |
| Aug 3, 26 | Maricich Yuri | buy | 6,551 |
| Aug 3, 26 | Gold Kelly | buy | 6,551 |
| Aug 3, 26 | Mandel-Brehm Josh | buy | 6,551 |
| Jun 10, 26 | WILLIAMS DOUGLAS E | other | 28,000 |
| Jun 10, 26 | Young Richard A | other | 28,000 |
| Jun 10, 26 | Schwab Andrew J. | other | 28,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our CAMP coverage
Recent articles, reports, and earnings notes.
No research on CAMP yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CAMP report →Canadian GoldCamps Enters into Agreement to Acquire Stealthwall West Gold Project in Northeastern Québec
thenewswire.com · Aug 18
CAMP4 Therapeutics Corporation (CAMP) Reports Q2 Loss, Tops Revenue Estimates
zacks.com · Aug 13
CAMP4 Reports Second Quarter 2026 Financial Results and Corporate Highlights
globenewswire.com · Aug 13
CAMP4 advances rare disease treatment for SYNGAP1 into human trials
cnbc.com · Aug 6
SIX FLAGS GREAT AMERICA ANNOUNCES CAMP TIMBER TRAIL, AN ALL-NEW FAMILY ADVENTURE FOR 2027
prnewswire.com · Aug 6
CAMP4 Therapeutics Announces Second Closing of $100 Million Private Placement
globenewswire.com · Aug 4
Canadian GoldCamps Completes Independent NI 43-101 Technical Report for the Mercator Gold Project
thenewswire.com · Jul 28
CAMP4 Therapeutics Secures Australian Regulatory Clearance to Initiate First-in-Human Clinical Trial of CMP-002 in Patients With SYNGAP1-Related Disorder
globenewswire.com · Jul 27
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.